But lowering triglycerides isn't the only MOA of VASCEPA (EVAPORATE resukts in November will likely show plaque reduction and reduction of inflammation) and further to get a CVD label Matinas would need to do a 5-year outcomes study which they can't afford and will consume significant funds.